"Eli Lilly Rises on Obesity Drug Demand, Eyes $1,033 Target"
Eli Lilly CEO on prospect of insurance companies covering weight loss drugsПодробнее
Lilly Pulls Ahead of Novo in Obesity Drug RaceПодробнее
Eli Lilly CEO on obesity drugs, future of companyПодробнее
Eli Lilly's obesity drug will be a tailwind for the stock, says BMO's Evan SeigermanПодробнее
Eli Lilly CEO: We know there's high demand for weight-loss drugs and we're ready to meet itПодробнее
People are 'scratching and clawing' for negative narrative around obesity drugs: Mizuho's Jared HolzПодробнее
Novo Nordisk and Eli Lilly will dominate the obesity drug market long-term, says Mizuho's Jared HolzПодробнее
Eli Lilly CEO on Fighting Obesity, Developing New DrugsПодробнее
Eli Lilly CEO on Fighting Cancer and Obesity, Drug PricingПодробнее
Eli Lilly Now Selling Zepbound Vials at 50% DiscountПодробнее
FDA Approves Eli Lilly’s Zepbound Drug for Weight LossПодробнее
Eli Lilly Set to Launch Obesity Drug Tirzipatide in India Amidst Weight Loss CrazeПодробнее
Eli Lilly sells cheaper Zepbound option to meet demand | REUTERSПодробнее
Eli Lilly Lowers 2024 Revenue Forecast as Weight Loss Drug Demand Slows | WORxK Global NewsПодробнее
Lilly invests $3 billion to expand Wisconsin plant as obesity drug demand soarsПодробнее
Pharmaceutical Company Eli Lilly Caps Out-of-Pocket Cost for Insulin at $35Подробнее
Will Eli Lilly’s Weight-Loss Drug Be a Gamechanger? | Vantage with Palki SharmaПодробнее
Potential for Weight-Loss Drugs Boosts Eli LillyПодробнее
Eli Lilly CEO on side effects from weight loss drugsПодробнее
Eli Lilly’s Affordable Weight Loss BreakthroughПодробнее